South Korean pharmaceutical firm United Pharmaceutical is enacting a major strategic shift, pivoting from conventional drug progress to focus on improved generic medications. This move comes amid increasing pressure on pharmaceutical pricing in south Korea and a growing global demand for more affordable healthcare options. The company projects this transition will yield 330 billion Korean won-roughly $250 million USD-in revenue by 2026, signaling a fundamental restructuring of its business model [[1]], [[2]].
United Pharmaceutical Shifts Focus to Generic Drug Development, Targets $330 Billion in Revenue
United Pharmaceutical is strategically pivoting towards the development and sales of improved generic drugs, a move the company believes will position it for significant growth in the coming years. This shift comes as the South Korean pharmaceutical market experiences changes in drug pricing regulations, creating new opportunities for companies specializing in these types of medications.
The company aims to achieve 330 billion Korean won (approximately $250 million USD) in revenue by 2026, largely driven by its expanded portfolio of improved generics. According to company statements, this strategy represents a fundamental change in its business model, effectively transforming United Pharmaceutical into a new drug entity.
“Attacking management is the answer in the face of drug price cuts,” stated Kang Deok-young, the company’s CEO. This aggressive approach reflects the challenging market conditions and the need to maintain profitability amidst pricing pressures.
United Pharmaceutical anticipates that improved generic drugs will account for 60% of its overall business. The company’s focus on this segment is a response to evolving market dynamics and a desire to capitalize on the growing demand for affordable healthcare solutions. This transition is expected to bolster the company’s financial performance and strengthen its position within the competitive pharmaceutical landscape.
The move towards improved generics is seen as a strategic adaptation to the changing “drug price revision landscape.” The company is positioning itself to thrive in an environment where cost-effectiveness and accessibility are paramount.
